Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon proposes Hemopurifier as a treatment candidate for H1N1virus

Aethlon Medical : 05 May, 2009  (Company News)
Aethlon Medical confirms the Aethlon Hemopurifier is a candidate to treat the H1N1 Swine flu virus.
The Hemopurifier is a first-in-class medical technology that assists the immune response in combating infectious disease through the selective adsorption of circulating viruses and immunosuppressive proteins.

In the case of pandemic influenza, the Hemopurifier has previously proven effective in capturing the reconstructed Spanish flu of 1918 virus (1918rv), the H5N1 avian influenza virus (Bird Flu), and would likely capture H1N1 swine flu as the technology selectively captures influenza viruses by haemagglutinin (HA) and neuraminidase (NA) glycoproteins that coat the virus, even when influenza mutates to be resistant against drug and vaccine therapies. As an example, H5N1 bird flu virus was documented to be resistant against Tamiflu, the globally stockpiled antiviral treatment for influenza.

'It is important that our shareholders understand we are fully cognizant of the potential opportunity associated with the emerging swine flu pandemic,' stated Aethlon Chairman and Chief Executive Officer, Jim Joyce. 'However, until this viral threat demonstrates resistance against Tamiflu treatment stockpiles, we shall remain focused on progressing our clinical and commercialization efforts against well-established infectious disease targets.'

Since the beginning of 2009, the Hemopurifier has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. As a result, Aethlon believes the Hemopurifier is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies. Such data further reinforces the position of the Hemopurifier as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Should H1N1 Swine Flu evolve to be highly virulent and resistant to treatment stockpiles, the Hemopurifier is positioned to become a first-line treatment countermeasure to strengthen the clinical benefit of both established and candidate drug treatments.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo